Cardiovascular Research with ALZET® Pumps
Animal models of human cardiovascular disease such as those for spontaneously hypertensive rats (SHR) or balloon injury have long represented an important area of research and discovery. Whether studying hypertension, restenosis, nitric oxide (NO) and NO synthase inhibitors, or the renin-angiotensin system, the use of ALZET osmotic pumps to deliver agents continuously provides a powerful tool for experimentation. ALZET pumps have been used to deliver antihypertensive drugs, angiogenic agents, compounds which inhibit vascular restenosis, and hormones with cardiovascular effects. The reference lists* shown below contain examples of these types of research.
If you are interested in a specific agent and did not find it listed above, check the index by Agent Administered.
*Some of these bibliographies may be large and take a short while to display. These bibliographies are updated frequently. As the references are listed most recent first, you may wish to truncate your printing to ten pages or less.
Looking for references? We can help!
Since 1977, scientist around the world have used ALZET pumps to conduct their research, publishing their results in high-impact journals. The ALZET bibliography now contains over 16,000 publications! We can perform a custom search for references relevant to your research.
- Ensure around-the-clock exposure to test agents at predictable levels
- Permit continuous administration of short half-life proteins and peptides
- Provide a convenient method for the chronic dosing of laboratory animals
- Minimize unwanted experimental variables and ensure reproducible, consistent results
- Eliminate the need for nighttime or weekend dosing
- Reduce handling and stress to laboratory animals
- Small enough for use in mice or very young rats
- Allow for targeted delivery of agents to virtually any tissue
- Cost-effective research tool
What researchers are saying...
“The infusion treatment using implanted ALZET-type osmotic mini-pumps proved to be superior to both S.C. and I.V. infusion applied twice a day for 2 weeks.” (p. 586) Szende et al., Anti-Cancer Drugs 2003;14:585-588.